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This paper examines whether the composition of medical research responds to changes in disease incidence
and research opportunities. The paper also provides new evidence on induced pharmaceutical innovation.
In both cases we use the change in the demographic structure of the market (measured by age structure
and obesity prevalence) to test the induced innovation hypothesis. Technological opportunity is calculated
from estimates of structural productivity parameters. The extent of inventive activity is measured from
the MEDLINE database on 16 million biomedical publications. We match these data with data on
disease incidence. We show that medical research responds to changes in disease incidence and research
opportunities. We also find that pharmaceutical innovation responds to aging- and obesity-induced
changes in potential market size.
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One key virtue of for-pro￿t allocation is that decisions made by for-pro￿t ￿rms must nec-
essarily respond to changes in the market. That is, for-pro￿t producers must shape their
products to ￿t the demands of their consumers or clients, or else risk failure. There is
abundant evidence that for-pro￿t producers (for instance in the pharmaceutical industry)
innovate according to market demand (see Acemoglu and Linn, 2004).
Non-pro￿t allocation, on the other hand, imposes looser budget constraints on ￿rms
(Lakdawalla and Philipson, 2006). In principle at least, loose constraints could insulate
non-pro￿t producers from the raw demand of the market, and hence divorce production
decisions from demand. This sort of reasoning has often been applied to academic publishing,
and is a good working de￿nition of an academic ivory tower. While there may be good
reasons to insulate some markets with non-pro￿t production from the vagaries of the market,
academic medicine is not such a market. Despite the evident importance that the non-pro￿t
producers of academic medicine respond to the market (that is, the epidemiology of patient
health), there is little extant evidence that they do. In fact, to our knowledge there is little
extant evidence on whether non-pro￿t allocation induces a link between market demand and
innovation in any market.
We show that the direction of medical research does respond to changes in the expected
number of people who bene￿t from the research and changes in technological opportunity.
The identi￿cation of the technological opportunity e⁄ect relies on our analysis of a formal
model of optimal allocation of research e⁄ort. The analysis enables us to estimate the struc-
tural productivity parameters that govern technological opportunity. The disease incidence
e⁄ect is identi￿ed using aging- and obesity-driven exogenous variation in disease incidence.
To our knowledge our study is the ￿rst study on non-pro￿t innovation that identi￿es the tech-
nological opportunity e⁄ect and the ￿rst study on non-pro￿t innovation that uses exogenous
variation to identify the induced innovation e⁄ect. We also present evidence on aging- and
1obesity-induced pharmaceutical innovation. While the ￿nding of aging-induced pharmaceu-
tical innovation replicates a ￿nding in the existing literature the ￿nding of obesity-induced
pharmaceutical innovation is new.
The empirical analysis is facilitated by the construction of a match between a medical
vocabulary and data on disease incidence. This match enables us to use the massive indexed
MEDLINE database on 16 million biomedical publications to measure innovation in medi-
cine. To our knowledge our study is the ￿rst to take advantage of the panel nature of this
database which is rich in its information content and thereby has great potential for future
innovation research.
2 Background
The literature on the determinants of non-pro￿t innovation is near non-existent. Lichtenberg
(1999) and Lichtenberg (2006) are exceptions. Lichtenberg (1999) ￿nds a positive correlation
between public biomedical funding and both the disease prevalence and the disease severity.
Lichtenberg (2006) ￿nds a positive correlation between cancer incidence and the number of
biomedical publications. Unlike these studies, we use panel data and exogenous variation
in the disease incidence to identify the induced innovation e⁄ect, and we also determine the
technological opportunity e⁄ect.
Our contribution builds on two connected strands of literature on for-pro￿t innovation.
The induced innovation hypothesis originated in Hicks (1932) and Schmookler (1966). Recent
empirical studies of the induced innovation hypothesis in the pharmaceutical industry include
Acemoglu and Linn (2004), which we discuss below, Finkelstein (2004) and Lichtenberg
and Waldfogel (2003). Technological opportunity was examined ￿rst by Scherer (1965) and
Schmookler (1966), and more recently by Popp (2002) which we discuss below.
The studies most closely related to ours are Popp (2002) and Acemoglu and Linn (2004).
Popp (2002) uses data on energy prices and patenting activity across energy technologies
2over time and ￿nds a positive relationship between innovation and both energy prices and
technological opportunity.1 We too examine both induced innovation and the technologi-
cal opportunity e⁄ect. But in contrast with Popp (2002) our main focus is on non-pro￿t
innovation and we use data on biomedical publications to measure inventive activity.
Acemoglu and Linn (2004) use the change in age demographics to identify the e⁄ect of
market size on pharmaceutical innovation and ￿nd a positive empirical relationship.2 In
comparison, we use changes in both age demographics and obesity prevalence to identify the
induced innovation e⁄ect. Also, whereas Acemoglu and Linn (2004) measure the extent of
pharmaceutical innovation from new drug introductions, which re￿ ects for-pro￿t production,
we measure it from biomedical publications, which re￿ ects non-pro￿t production. An addi-
tional di⁄erence between our work and Acemoglu and Linn (2004) is that our main focus is
not on induced pharmaceutical innovation but on the determinants of medical research.
The methodology we use to estimate technological opportunity builds on the methodology
developed in the studies on patenting by Caballero and Ja⁄e (1993) and Ja⁄e and Trajtenberg
(1996). In comparison with these studies we derive the estimating equation from a model of
optimal allocation of research e⁄ort. This enables us to estimate the structural productivity
parameters. Moreover, the probability that a given knowledge cohort is used in research
depends also on the quality of other existing knowledge cohorts.
Our ￿nding of obesity-induced innovation is also related to the empirical studies on
preference externalities by Waldfogel (2003) and George and Waldfogel (2003). In these
studies the preference externality arises from racial characteristics whereas in our case the
preference externality is determined by the consumers￿decisions about body weight (to
the extent it is a decision). In a companion paper (Bhattacharya and Packalen, 2008) we
calculate the welfare e⁄ect of the induced innovation externality of obesity.
1Newell, Ja⁄ee and Stavins (1999) exploit the changes in energy prices and changes in the cost and energy
e¢ ciency of air conditioners to examine the e⁄ect of energy prices on the direction of technological change.
2DellaVigna and Pollet (2007) exploit the changes in the age demographics to study stock market returns.
33 Theory
We ￿rst present a model of medical research. In the second subsection we discuss why
technological opportunity in medical research is also a measure of pharmaceutical innovation.
3.1 A Model of Medical Research
We distinguish between two types of medical research: drug-related medical research and
other medical research. In both cases, following the induced innovation hypothesis, the op-
timal research e⁄ort is increasing in disease incidence. In the case of drug-related medical
research the research e⁄ort is also in part determined by technological opportunity as new
research opportunities are presented by the discovery of new active ingredients. The phar-
maceutical research that leads to the discovery of new active ingredients precedes the type
of medical research examined here. The model of allocation of other medical research is a
special case of the model of allocation of drug-related medical research. Therefore, we only
consider the allocation of drug-related medical research in the formal analysis.
We divide drug-related medical research into mutually exclusive categories by the disease
examined in the research and by the active ingredient used in the research. We also lump
together the ingredients by their year of discovery (cohort), denoted by f. We ￿rst consider
the optimal allocation of drug-related research e⁄ort in the disease i in year t across cohorts
f. We assume that the bene￿t of research on disease i that uses ingredients from a cohort f
depends on a measure of the baseline productivity of the cohort of ingredients f in research
on the disease i, denoted by aif, on the elapsed time t ￿ f since the initial discovery of the
ingredients, on the extent of the research e⁄ort in year t that uses an ingredient from the
cohort f in research on the in disease i, denoted Nitf, on the expected number of people
with the disease i in year t; denoted by Mit, and on other factors, denoted by "itf:
Speci￿cally, we assume that the bene￿t from research on the disease i in year t that uses











In this expression the factor
￿
1 ￿ e￿￿2(t￿f)￿
represents the lag after the discovery of the
ingredients in the cohort f before the full potential of this cohort of ingredients in medical
research on the disease i is revealed. The factor e￿￿1(t￿f) represents the eventual decay in
the usefulness of the cohort of ingredients f in medical research as the properties of this
cohort of ingredients become established knowledge.3 We assume that the variable "itf is
observable to the medical researchers and satis￿es E ["itf] = 0.
The range of cohorts f is ff0;f0 + 1;:::;tg in year t. The total bene￿t from research on





























f=f0 f￿if ￿ e￿￿1(t￿f) ￿ [1 ￿ e￿￿2(t￿f)] + "itfg
: (3)
We now consider the optimal allocation of research e⁄ort across diseases. We assume
3We do not model explicitly the e⁄ect that the amount of research in the preceeding years may have on
the bene￿t from research in a given year. This assumption is innocuous if marginal research in each year
does not in￿ uence the quality of research opportunities in future years.
4Denoting the optimal level of e⁄ort by N￿














itf0 for all (i;t;f;f0): Denoting citf ￿
￿if ￿ e￿￿1(t￿f) ￿
￿
1 ￿ e￿￿2(t￿f)￿
+ "itf this condition can be rewritten as citf ￿ N￿
itf0 = N￿
itf ￿ citf0 for all
(i;t;f;f0): Taking the sum of both sides of the equation citf ￿ N￿
itf0 = N￿







f=f0 citf for all (i;t;f): Rearranging and using the de￿nitions of citf and
p￿
itf gives the relationship (3) in the text.
5that the overall bene￿t from research in year t is the sum of the bene￿t from research in















If the allocation of resources across cohorts of ingredients within a disease is optimal, using
the de￿nition of p￿
itf and the de￿nition Nit ￿
Pt
f=f0 Nitf the expression (4) for the overall



































f=f0 f￿if ￿ e￿￿1(t￿f) ￿ [1 ￿ e￿￿2(t￿f)] + "itfg
(6)
for all (t;i) by the ￿rst-order conditions for the optimum.
The factor
Pt
f=f0f￿if ￿ e￿￿1(t￿f) ￿
￿
1 ￿ e￿￿2(t￿f)￿
+ "itfg in the equation (6) is a mea-
sure of technological opportunity in research on the disease i in year t: Denoting this








￿ Mit ￿ Kit: Assuming that Nit > 0 and Kit > 0 for all (i;t)
this can be rewritten as
lnNit = lnKit + lnMit + ￿t; (7)









The empirical predictions of this model are two-fold. First, by the equation (7) the model
predicts a proportional relationship between research e⁄ort in a disease and technological
opportunity for research on the disease and a proportional relationship between the research
e⁄ort in a disease and the disease incidence. With a di⁄erent functional form for the overall
6bene￿t from research both relationships would still be positive but non-proportional. We
allow for this possibility in our empirical framework. Second, the model predicts the rela-
tionship (3) between the parameters ￿if; ￿1 and ￿2 that govern technological opportunity
Kit and the probability that a cohort of ingredients is used in research. We use this pre-
dicted relationship to estimate the parameters ￿if and the parameters ￿1 and ￿2 in order to
construct an estimate of technological opportunity Kit.
As we can only construct a measure of technological opportunity for drug-related medical
research, the relevant empirical prediction of the corresponding analysis for the case of other
medical research is simply a proportional relationship between the disease incidence and the
research e⁄ort in the disease. As in the case of drug-related research, di⁄erent assumptions
about the preferences would imply that the relationship is positive but non-proportional.
We allow for this possibility in the empirical analysis.
3.2 Pharmaceutical Innovation
Acemoglu and Linn (2004) present a formal analysis of induced innovation that predicts
a positive relationship between the extent of pharmaceutical innovation and the potential
market size for new drugs. While their focus is on the e⁄ect of market size on the ￿ ow
of pharmaceutical innovation, Acemoglu and Linn (2004) also note a positive empirical
relationship between the stock of drugs and potential market size.
Our measure of research opportunity in drug-related medical research is determined by
the extent of past pharmaceutical innovation. We can therefore examine the relationship
between the extent of pharmaceutical innovation and the potential market size indirectly by
comparing the changes in the relative potential market sizes across diseases and the changes
in technological opportunity across diseases. The induced innovation hypothesis predicts a
positive relationship between these variables.5
5An advantage of our indirect approach over the direct approach of Acemoglu and Linn (2004) is that
variations in the measure of technological opportunity capture di⁄erences in the relative importance of
74 Empirical Strategy
We ￿rst discuss in turn the estimation of technological opportunity, the identi￿cation of
the technological opportunity e⁄ect, and the identi￿cation of the market size e⁄ects. The
regression models that we use to estimate the e⁄ects are then presented in the last subsection.
4.1 Estimation of Technological Opportunity
In the model of medical research a measure of technological opportunity in drug-related













where the parameters ￿if specify the baseline productivity of each cohort, the parameter ￿1
governs the eventual decay in the research potential of a cohort of ingredients, the parameter
￿2 governs the rate at which the full potential of a cohort of ingredients for research is revealed
to researchers, and "itf denotes other factors that in￿ uence the productivity of research that
uses ingredients from the cohort f. We assume that E["itf] = 0 and that "itf is independent
and identically distributed.
The model also predicts the relationship (3) between the probability p￿
itf that an ingre-
dient from the cohort f is used in research on the disease i in year t and the parameters










relationship (3) may be rewritten as
p
￿






di⁄erent drugs. A possible disadvantage of our approach is that the timing of the e⁄ect that the discovery
of a new ingredient has on the measure of the technological opportunity does not necessarily coincide with
the timing of the stream of pro￿ts from the discovery of the new ingredient.
8When t￿f0 is large, we have that
Pt
f=f0 "itf ￿ 0. Applying this simpli￿cation modi￿es the





















f=f0 ￿if ￿ e￿￿1(t￿f) ￿ [1 ￿ e￿￿2(t￿f)]
(11)
The econometric challenge is to estimate the parameters ￿if, ￿1 and ￿2. We ￿rst estimate
the parameters ￿1 and ￿2 using non-linear least squares applied to the equation (9) while
assuming arbitrary ￿xed values for the parameters ￿if and ￿it:6 To estimate the parameters
￿if we then use the following iterative procedure:
￿ We start by calculating initial estimates of ￿it by plugging in the estimates of the
parameters ￿1 and ￿2 as well as arbitrary (starting) values of ￿if into the expression
(10).7
￿ Using the estimates of the parameters ￿it and the estimates of the parameters ￿1 and
￿2, we estimate the parameters ￿if by least squares applied to the equation (9) and
holding ￿it; ￿1 and ￿2 ￿xed.
￿ We recompute the estimates of ￿it by plugging in the estimates of ￿if and the estimates
of ￿1 and ￿2 into the expression (10). If the new value of the estimate of ￿it is
su¢ ciently close to the old value, we declare convergence. If not, we iterate the previous
step until convergence.





+"itf: Omitting a multiplicative constant in this speci￿cation is both innocuous
and necessary because the true value of the parameter ￿2 is typically very small and the variation in t ￿ f
is limited which make the factor
￿
1 ￿ e￿￿2(t￿f)￿
approximately equal to ￿2 ￿ (t ￿ f) in the sample.
7We assume that ￿if = 1 for all i;f:
9This iterative procedure yields estimates of the parameters ￿if. We then generate our
estimate of technological opportunity using the estimates ^ ￿if; ^ ￿1 and ^ ￿2 and the formula
^ Kit ￿ E[Kitj^ ￿if; ^ ￿1; ^ ￿2] ￿
t X
f=f0







4.2 Identi￿cation of the Technological Opportunity E⁄ect
As the variation in technological opportunity over time is likely to be correlated with the
variation in the unobserved determinants of medical research over time, we employ ￿xed
e⁄ects approaches in which the technological opportunity e⁄ect is identi￿ed by comparing the
changes in technological opportunity with the changes in the research e⁄ort across diseases
over time.
The model of medical research predicts that within a disease the distribution of research
across cohorts of ingredients is independent of the total amount of research on the disease.
With a di⁄erent functional form for the overall bene￿t from medical research this would
not hold. Consequently, changes in the level of drug-related research on a disease could be
correlated with changes in the estimated technological opportunity in research on the disease
even if there was no causal relationship from technological opportunity to the level of the
drug-related research e⁄ort.
However, the unobserved e⁄ects that in￿ uence the level of drug-related research e⁄ort
and the unobserved e⁄ects that in￿ uence the level of other medical research e⁄ort are likely
to be correlated. Therefore, if there is indeed reverse causality from the level of research
e⁄ort to the measure of technological opportunity, there will be a positive relationship also
between the estimated technological opportunity and the level of other medical research. In
contrast, if there is no reverse causality from the level of research e⁄ort to the measure of
technological opportunity, there will not be a positive relationship between the estimated
technological opportunity and the level of other medical research. We can therefore test for
10the presence of the reverse causality by including the estimate of technological opportunity
also into the analyses of the determinants of other medical research.
4.3 Identi￿cation of Market Size E⁄ects
As is well recognized in the literature on induced innovation, the causal e⁄ect of the poten-
tial market size on the extent of innovation cannot be inferred from the relationship between
observed innovation and the observed market size due to the endogeneity of the observed
market size. Acemoglu and Linn (2004) circumvent this problem by examining the rela-
tionship between the changes in pharmaceutical innovation and the changes in the potential
market size that are caused by the exogenous changes in the age demographics of the popu-
lation. The key conditions to the success of this identi￿cation strategy are that the e⁄ect of
aging on disease incidence varies across diseases, that the age demographics of the population
have changed over time, and that the changes in the age demographics are mostly caused by
changes in fertility and are therefore exogenous to the rate of pharmaceutical innovation.
We follow this general identi￿cation strategy in our analyses of induced pharmaceutical
innovation but in constructing the potential market size we take into account both the e⁄ect
that the change in the age demographics has had on the disease incidence over time and the
e⁄ect that the obesity epidemic has had on the disease incidence over time. As the potential
market size is measured by the disease incidence, we naturally use the same methodology in
the analyses of induced innovation in medical research.
The e⁄ect that an obesity-induced change in the potential market size has had on the
extent of innovation may be di⁄erent than the e⁄ect that an aging-induced change in the
potential market size has had on the extent of innovation if one type of e⁄ect has been better
understood than the other or if the change in the age demographics was more expected than
the obesity epidemic. We allow for this possibility by decomposing the changes in the
potential market size into aging-induced changes and obesity-induced changes.
114.4 The Empirical Models
We use two types of ￿xed e⁄ects approaches. In one case we include disease ￿xed e⁄ects and
year ￿xed e⁄ects. Using this strategy the identifying variation comes from the variation in
the regressor (either technological opportunity or potential market size) relative to all other
diseases. In the other case we include disease ￿xed e⁄ects and the interactions of disease
class ￿xed e⁄ects and year ￿xed e⁄ects. Using this strategy the identifying variation comes
from the variation in the regressor (either technological opportunity or potential market
size) relative to all other diseases in the same disease class. The parameters of interest will
be di⁄erent in these two speci￿cations if the elasticity of substitution of research e⁄ort is
di⁄erent between diseases within each disease class than it is between diseases in di⁄erent
disease classes.
The ￿rst empirical speci￿cation that we use to examine induced pharmaceutical innova-
tion is
ln ^ Kit = ￿M lnM
TOTAL
it + ￿xed e⁄ects + "it: (13)
Here Kit is the estimated measure of technological opportunity for drug-related research on
the disease i in year t.8 The variable MTOTAL
it is the potential market size for the disease i













In the expression (14) the parameter ￿i;j;k is the incidence of the disease i among people in
the age group j who are in the Body-Mass-Index (BMI) group i, the parameter sAGE
j;t is the
share of people in the age group j in year t; and the parameter sBMI
j;k;t is the share people in
8See the subsection 3.2 for why the measure of technological opportunity in drug-related medical research
is also a measure of pharmaceutical innovation.
12the age group j who are in the BMI group k in year t:9;10 The age groups are 0-18, 18-35,
35-50, 50-65 and 65+. The BMI groups are 18.5-25, 25-30 and 30-50.11
In the second empirical speci￿cation for induced pharmaceutical innovation we decompose
the changes in the potential market size into aging-induced changes and obesity-induced
changes. This second empirical speci￿cation is
ln ^ Kit = ￿A lnM
AGING
it + ￿O lnM
OBESITY














is the potential market size in year t for the disease i when the body weight distribution in
year t is set to be the same as the body weight distribution is in the initial year t0 in the













is the potential market size in year t for the disease i when the age distribution in year t is
set to be the same as the age distribution is in the initial year t0 in the sample and only the
body weight distribution varies across time.12 A positive estimate of the parameter ￿A is
9The parameters ￿i;j;k; sAGE
j;t and sBMI
j;k;t are estimated from data on the disease incidence and from data
on demographics prior to the estimation of the induced innovation model. The data sources are discussed in
the next section. As we use disease and year ￿xed e⁄ects we can ignore population and population growth
in estimating the potential market size.
10In estimating the disease incidence we allow for the parameter to vary by sex, race (black/non-black),
insurance status (private/not private) and year but for expositional simplicity we omit these issues in the
text. As we don￿ t measure changes in the insurance rates across time we do not examine the e⁄ect that
changes in the insurance rates across time may have on potential market size and innovation.
11For the age group 0-18 we do not distinguish the disease incidence by body weight and therefore assume
that sBMI
1;1;t = 1; sBMI
1;2;t = 0 and sBMI
1;3;t = 0 for all t:
12The decomposition arises as follows. Let Mit0 denote the incidence of the disease i in the initial year t0:
Let RAGING
it denote the e⁄ect of aging alone on the incidence of the disease i so that if only aging a⁄ected the
incidence of the disease i the disease incidence would be Mit0RAGING
it in year t: Let ~ ROBESITY
it denote the ad-
ditional e⁄ect of the obesity epidemic on the incidence of the disease i so that if only aging and obesity a⁄ected
the incidence of the disease i the disease incidence would be Mit = Mit0RAGING
it ~ ROBESITY
it in year t: Let
13therefore evidence of aging-induced innovation and a positive estimate of the parameter ￿O
is evidence of obesity-induced innovation.
The empirical model that we use to analyze of the e⁄ect of technological opportunity and
the e⁄ect of the disease incidence on the level of medical research e⁄ort is13
lnNit = ￿K ln ^ Kit + ￿A lnM
AGING
it + ￿O lnM
OBESITY
it + ￿xed e⁄ects + "it: (18)
The variable Nit is a measure of medical research e⁄ort on the disease i in year t: As was
discussed in the subsection 4.2, we include the technological opportunity variable also in the
analyses of other medical research because if in the analyses of other medical research the
estimate of the parameter ￿K is close to zero it is an indication that a positive estimate of
the coe¢ cient ￿K for drug-related research is not a result of reverse causality.
5 Data
We postpone the discussion of the descriptive statistics until the beginning of the next
section. To estimate the disease incidence for each age and BMI group we use the Medical
Expenditure Panel Survey (MEPS) data from years 1996-2005.14 Each subject is followed in
MEPS for two years. For each subject we aggregate the observations in each year into one
ROBESITY
it denote the e⁄ect of obesity alone on the incidence of disease i so that if only obesity a⁄ected the
incidence of the disease i the disease incidence would be Mit0ROBESITY
it in year t: Because RAGING
it is small,
ROBESITY
it ￿ ~ ROBESITY























as regressors. Because the empirical speci￿cations include disease and year ￿xed e⁄ects we can replace these






















13Because the empirical results show that for medical research the e⁄ect of aging-induced changes in the
disease incidence and the e⁄ect of obesity-induced changes in the disease incidence are so di⁄erent we do not
show the results for the speci￿cation in which the two e⁄ects are restricted to be the same (the speci￿cation
in which the disease incidence is measured by MTOTAL
it ).
14Because the trends in the changes in the age and body weight distributions have been similar across the
developed nations we do not believe that using data on disease incidence, age demographics and obesity for
the United States but data on world-wide publications is a signi￿cant concern.
14observation. MEPS includes a list of self-reported diseases that are coded by the International
Classi￿cation of Diseases, Ninth Revision (ICD-9). MEPS does not include BMI information
for years 1996-2000. We therefore use the National Health Interview Survey (NHIS) data
from years 1996-2000 and the match between NHIS and MEPS to obtain BMI information
for the observations in those years. The resulting MEPS data includes 262,958 observations
on 149,737 subjects.15
We use the Surveillance Epidemiology and End Results (SEER) data from years 1975-
2004 to estimate the share of people in each age group in each year.16 For each age group we
use the NHIS data from years 1976-2005 to estimate the share of people in each BMI group
in each year.17
To measure medical research e⁄ort as well as technological opportunity in drug-related
medical research we use the MEDLINE database on approximately 16 million biomedical
publications, generally from 1950 to the present. Publications in the database are indexed
by the 2007 version of the Medical Subject Headings (MESH) vocabulary. MESH is a
hierarchical medical vocabulary of over 20000 di⁄erent terms.
Because the MEPS data on the disease incidence is indexed by the ICD-9 classi￿cation
system and the publications are indexed by the MESH vocabulary we construct a match
between the ICD-9 codes and the MESH vocabulary. We limit the match e⁄ort to diseases
for which the MEPS data includes at least 100 observations.18 We do not match ICD-9
codes that include either the word "Other" or the word "Unspeci￿ed" in the title because
these ICD-9 codes typically include a variety of di⁄erent diseases and are therefore di¢ cult
to match to the MESH vocabulary. Neither do we match diseases in the pregnancy category
15Except for subjects in the age group 0-18 we exclude subjects without either age or BMI information.
16We impute the values for 2005 by assuming that the change in the population in each age group from
2004 to 2005 was the same as it was from 2003 to 2005.
17We impute the values for 1975 by assuming the the body weight distribution was the same in 1975 as it
was in 1976.
18We exclude HIV/AIDS because the disease does not appear in the publications database until the early
1980s and because the variations in the incidence of HIV/AIDS are obviously not mainly driven by aging or
the obesity epidemic.
15(class 11), in the congenital category (class 14), in the perinatal category (class 15), in the
symptoms category (class 16), in the injuries category (class 17) or in the services category
(class V). These classes are excluded from the match e⁄ort both in order to limit the scope
of our match e⁄ort and because of the di¢ culty of matching diseases in these categories. If
a match from an individual disease to a MESH entry/entries is not possible we try to match
a group of ICD-9 codes to a MESH entry/entries.
The matched diseases and their matched MESH entry/entries as well as the unmatched
diseases are listed in the Appendix 1. The match yields 127 separate matches between a
disease or a group of diseases and a MESH entry/entries.19 The 127 diseases belong to 12
disease classes. Because MESH is a hierarchical vocabulary, we also count all research that is
indexed to any subnode of a matched MESH term as research that is related to the matched
disease or group of diseases.20
As the MESH vocabulary has changed over the years we make an e⁄ort to check that
the MESH terms for the matched diseases have not changed in a way that would in￿ uence
the estimate of the research e⁄ort. For the diseases for which the related publications from
a year during the sample period are likely to have been indexed by terms other than the
matched MESH entry/entries we exclude the observations from such years and from any
of the preceding years. In the Appendix 1 the match for such diseases is marked with an
asterisk and the year prior to which any observations are excluded.
To measure the extent of the research e⁄ort related to a disease we count the number
of publications that are matched to the disease. A publication may be indexed to multiple
diseases among the 127 matched diseases. We allow for this possibility by counting publi-
cations that are matched to more than one disease the same we would count the matches if
19The matched diseases account for 377,482 of the 745,355 disease mentions in the MEPS data.
20We manually remove several matches of ICD-9 diseases to terms for neoplasms in MESH when the same
neoplasm term is also mapped to a disease in the ICD-9 disease class 2 (neoplasms). MESH has 4982 disease
terms. The match maps 1338 terms in MESH to the 127 diseases. 51 of the matched terms are mapped to
2 diseases and one term in MESH is mapped to 3 diseases. All other terms are mapped to only 1 disease.
16each match was from a separate publication.
We identify active ingredients from the Federal Drug Administration (FDA) data on drug
approvals during 1939-2006. As we generally cannot distinguish between active ingredients
and their derivatives in the biomedical publications data, we consider the ￿rst word in the
list of approved active ingredients to be the ingredient name that we use in our study. This
yields a list of 1448 ingredients.
We search both the title and the abstract of every publication in the MEDLINE database
for each ingredient in the list of ingredients. We set the cohort (year of discovery) of an
ingredient to equal the year prior to the year in which the ingredient is ￿rst mentioned either
in the abstract or in the title of a publication. In estimating technological opportunity, we
measure the research e⁄ort in the disease i in year t that is related to the cohort f by the
number of publications in year t which are matched to the disease i and mention an ingredient
from the cohort f either in the title or in the abstract of the publication. A publication may
be associated with multiple cohorts of ingredients. We allow for this possibility by counting
publications which are matched to more than one cohort of ingredients the same way we
would count the matches if each match was from a separate publication.
We use several strategies to identify and measure drug-related medical research. The
￿rst is to classify all publications that are matched to an ingredient as being drug-related
medical research and count a publication that is matched to n di⁄erent cohorts of ingredients
as n units of research. The second is to classify all publications that are matched to an
ingredient as being drug-related medical research and count each such publication as one
unit of research. The third is to classify all publications that have a MESH term indexed
together with the "major topic" ￿ ag and the MESH quali￿er term "drug therapy", "drug
e⁄ects" or "pharmacology" as being drug-related research and count each such publication
as one unit of research. We call these three measures as DRUG 1, DRUG 2, and DRUG 3,
respectively.
17We also use several strategies to identify and measure other medical research. The ￿rst
is to classify all publications that are not matched to an ingredient as being other medical
research and count each such publication as one unit of research. The second is to classify
all publications that are not matched to an ingredient, that are not indexed are indexed with
any of the MESH quali￿er terms "drug therapy", "drug e⁄ects" or "pharmacology", and that
are also not indexed with the MESH term "Chemicals and Drugs" as being other medical
research and count each such publication as one unit of research. The third is to classify
all research that is indexed with the MESH quali￿er term "surgery" or "transplantation" as
being other medical research and count each such publication as one unit of research. We
call these three measures as OTHER 1, OTHER 2, and OTHER 3, respectively.
As the descriptive statistics discussed in the next section show there is a discontinuous
jump in the share of publications with abstracts in the database from 1974 to 1975. Also, a
number of diseases are indexed with di⁄erent MESH terms before 1975 and especially before
1970 than they are after 1975. For these reasons we choose 1975-2005 as our sample period.
When we determine the cohort of an ingredient we use the publications from years 1906-
2005. In estimating the parameters that govern technological opportunity we limit the limit
the range cohorts f to years 1960-2001 because there is a discontinuous jump in 1950 in the
number of publications that are indexed in MEDLINE and because there is a discontinuous
fall in the number of ingredients in a cohort from 2001 to 2002 due to the lag between the
year in which an ingredient is ￿rst mentioned in the publications database and the year of
FDA approval of the ingredient.21 Because of this lag, because many of the diseases are
indexed with di⁄erent terms before 1970, and because in the subsequent analysis our focus is
on the sample period 1975-2005, in estimating technological opportunity we limit the range
of the years t to 1970-2002.
21We multiply the initially estimated technological opportunity by a factor that compensates for trunca-
tion. We assume that the average baseline productivity is the same before and after any truncation point.
That is, the estimates are multiplied by f
P1
t￿f=1 e￿^ ￿1(t￿f) ￿ [1 ￿ e￿^ ￿2(t￿f)]g=f
Pt￿1960
t￿f=1 e￿^ ￿1(t￿f) ￿ [1 ￿
e￿^ ￿2(t￿f)]g for all years t ￿ 2001. For t > 2001 we also compensate for truncation due to the upper bound.
186 Results
We start with the descriptive statistics. All ￿gures and tables are in the Appendix 2. Fig-
ure 1a shows the age and body weight distributions during the sample period. For both
distributions the change has been gradual but the change in the body weight distribution
began more recently than the change in the age distribution. Figure 1b shows the e⁄ect that
the changes in the two distributions have had on the disease incidence for each disease from
the beginning of the sample period (1975) to the end of the sample period (2005). For both
variables there is considerable variation in the e⁄ect (from -10% to +20%). These identifying
variations are also not too correlated for the e⁄ects to be separately identi￿ed in most cases.
Figure 2a depicts the count of all publications (All Publications) and the count of pub-
lications with an abstract (Publications with an Abstract) by the year of publication. The
graph also shows the count of publications that are indexed to a disease (Publications In-
dexed with a Disease) and the count of publications that are indexed to a disease that is
matched to an ICD-9 disease by our match (Publications Matched). A publication may be
indexed to more than one disease and, consequently, our match may match a publication to
more than one ICD-9 disease. Therefore, the count of matches of publications to a disease
(Publication-Disease Matches) is higher than the number of publications matched to at least
one disease (Publications Matched).
Figure 2b depicts the count of matches to one of the 127 diseases for the three measures
of drug-related medical research in each year and Figure 2c depicts the count of matches to
one of the 127 diseases for the three measures of other medical research in each year. The
count of publications for each measure is an important determinant of the precision of our
estimates because the variance of the share of publications that are related to a disease is
expected to be inversely related to the count of publications that are related to the disease
and the estimated e⁄ects are identi￿ed from the e⁄ects on the share of publications that are
related to each disease.
19We ￿rst estimate the parameters ￿if and the parameters ￿1 and ￿2 that govern the mea-
sure of technological opportunity using the iterative procedure described in the subsection
4.1. The estimates of the parameters ￿1 and ￿2 are ^ ￿1 = 0:0628 (s.e. 0:0045) and ^ ￿2 = 0:003
(s.e. 0:0004): Figure 2d shows that the predicted probability that is calculated based on
the estimates ^ ￿1 and ^ ￿2 as a function of the ingredient age t ￿ f tracks the mean of the
observed probability closely except for when the ingredient age is 35 and over. The share
of publications that use ingredients aged 35 and over is arti￿cially in￿ ated by the fact that
the MEDLINE database consists mostly of publications published after 1950 and therefore
our methodology of assigning the year of discovery of each ingredient assigns the year of
discovery between 1950 and 1965 for a disproportionate number of ingredients as can be
seen from Figure 2e.22
We ￿rst use the constructed measure of technological opportunity in drug-related med-
ical research as a proxy for pharmaceutical innovation to examine the induced innovation
hypothesis for pharmaceutical innovation. Because we expect the variance of the dependent
variable to be inversely related to the count of publications on the disease the observations
are weighted by the total count of matches to an ingredient cohort (measure DRUG 1) for
the disease during the sample period.23 The results are shown in Table 1.
Columns 1 and 2 show that when the potential market size e⁄ect is identi￿ed from
changes relative to diseases within each disease class there is strong evidence for the induced
innovation hypothesis both when the e⁄ects of aging and obesity are identi￿ed jointly and
when the e⁄ects are identi￿ed separately.24 Columns 3 and 4 show that when the potential
market size e⁄ect is identi￿ed from changes relative to all other diseases the induced inno-
22Moreover, the precision of the estimates for ingredient ages 35 and over is in￿ uenced by the small number
of observations in the data on ingredients aged 35 and over.




24The interpretation of the point estimates is straightforward. For example, the point estimate in the
column 1 implies that a one percent increase in potential market size increases pharmaceutical innovation
by three percent. The point estimates are consistent with the ￿ndings in Acemoglu and Linn (2004) who
focus on aging-induced pharmaceutical innovation.
20vation hypothesis is supported when the e⁄ects are identi￿ed jointly but the coe¢ cients are
no longer statistically signi￿cant when the e⁄ects are identi￿ed separately. Figures 3a and
3b depict the empirical relationship for the speci￿cation analyzed in column 1. The positive
relationship is clearly not a result of outliers. The relationship is even more robust when we
only consider the 50% of the diseases with the most publications. This supports the use of
weighted regressions in the analysis.
Before we examine drug-related medical research and other medical research separately,
we ￿rst examine the determinants of all medical research. The count of all publications,
denoted by NALL
it , that is used in this analysis corresponds to the measure Publication-
Disease Matches in Figure 2a. The results are shown in Table 2.25
Columns 1 and 2 show that aging-induced increases in the disease incidence have increased
the medical research e⁄ort in the disease. In contrast, there is no evidence of a corresponding
e⁄ect for obesity-induced changes in the disease incidence. Columns 3 and 4 show at best a
weak relationship between technological opportunity for drug-related research on a disease
and the amount of total research on the disease. Columns 3 and 4 also show that the
inclusion of technological opportunity variable renders the e⁄ect of aging-induced changes
in the disease incidence statistically insigni￿cant. However, as can be seen from Figure 3c,
which depicts the ￿xed e⁄ects speci￿cation analyzed in column 3, with the exception of the
outlier disease 299 there is a robust positive relationship between aging-induced changes in
the disease incidence and the changes in the overall research e⁄ort in the disease. Columns
5 and 6 show that when the disease 299 and the two other children￿ s mental health diseases
(314 and 315) are excluded, the relationship between aging-induced changes in the disease
incidence and the overall research e⁄ort in the disease is again statistically signi￿cant.
Because the change in the age distribution has had such an unusual e⁄ect on the predicted
25The observations are weighted by the total count of publications matched to the disease during the
sample period. That is, each observation is weighted by
P2005
t=1975 NALL
it . The number of observations varies
across columns because an observation is omitted if either ^ Kit = 0 or NALL
it = 0:
21disease incidence for the disease 299 (see Figure 1b) and because the dramatic increases in the
number of diagnoses and research interest in the children￿ s mental health diseases have been
well recognized but without agreement over the causes of this, in the subsequent analyses
we exclude the children￿ s mental health diseases.26
The results for drug-related research are shown in Table 3.27 There is robust evidence
across the three measures of drug-related research and the two ￿xed e⁄ects speci￿cations both
for the hypothesis that technological opportunity is a determinant of the allocation of drug-
related research e⁄ort across diseases and for aging-induced changes in the composition of
research. The robustness of the technological opportunity estimate presented in the column
1 is illustrated in Figure 3d. In contrast, there is no evidence in any of the speci￿cations
for a positive relationship between obesity-induced changes in the disease incidence and the
amount of drug-related research on the disease. If anything, the results suggest that there
may be a negative relationship between obesity-induced changes in the disease incidence and
the extent of drug-related research on a disease. We return to this issue after discussing the
corresponding results for other research.
The results for other medical research are shown in Table 4.28 For all speci￿cations
the estimate of the coe¢ cient on the technological opportunity is much smaller than the
corresponding estimate was for the three measures of drug-related research, and except for
26Research on children￿ s mental health diseases has increased dramatically since the early 1990s and this
increase is undoubtedly tied with the increase in the number of diagnoses for these diseases during the same
period. While the unusual increase in the interest in these diseases is well known there is no agreement on
why the increase has occurred. One explanation is that the increase in the diagnoses and the increase in
research to the children￿ s mental health diseases are consequences of the availability of dramatically better
treatment options for these diseases, especially in the form of better knowledge of the e⁄ects of several
drugs such as methylphenidate (ritalin). Methylphenidate was discovered in the 1950s and our measure of
technological opportunity is unable to predict the increase in research to these diseases because the increase
happens 40 years after the discovery of the drug.
An alternative explanation for why the disease 299 and to a lesser extent also the two other children￿ s
mental health diseases (314 and 315) are outliers is that during the sample period there may have been a
general disproportional increase in research to diseases that primarily a⁄ect the children. We plan to explore
this possibility in future research.








22￿rst ￿xed e⁄ects speci￿cation for the most inclusive measure of other research OTHER 1
(see column 1), which is the most likely of the three measures to include also some drug-
related publications, the relationship is also statistically insigni￿cant. As was discussed in
the subsection 4.2, the ￿nding of no relationship between the level of other research and the
technological opportunity in drug-related research is evidence against the possibility that
reverse causality is the reason for the observed positive relationship between the measure of
technological opportunity and the extent of drug-related research.
The results for the measures OTHER 1 and OTHER 2 that are reported in columns 1 and
2 and in columns 3 and 4 also provide evidence of aging-induced changes in the composition
of other medical research across diseases but show no evidence of obesity-induced changes
in the composition of other medical research across diseases. The results for surgery-related
research (the measure OTHER 3) in columns 5 and 6 show that the relationship between
aging-induced changes in the incidence of a disease and the extent of surgery-related research
on the disease is positive but not statistically signi￿cant. As was the case for drug-related-
research, the results for surgery-related research suggest a possible negative relationship
between obesity-induced changes in the incidence of a disease and the extent of surgery-
related research on the disease. We now examine these relationships with additional analyses
that are reported in Table 5.
In the analyses that are reported in columns 1 and 2 the logarithm of the ratio of the
most restrictive measure of drug-related research and all research is set as the dependent
variable.29 As expected, the results indicate a positive relationship between technological
opportunity in drug-related research on a disease and the share of research on the disease
that is drug-related. Because aging-induced changes are expected to in￿ uence drug-related
research and all research the same way, the ￿nding that there is no statistically signi￿cant
relationship between aging-induced changes in the disease incidence and changes in the share




23of research on a diseases that is drug-related research is as expected. However, the point
estimate still leaves open the possibility that drug-related research reacts to changes in the
disease incidence more strongly than all medical research. As in the earlier analyses of
drug-related research the obesity-induced changes in the disease incidence have a negative
but statistically insigni￿cant relationship with the changes in the dependent variable. This
suggests that an obesity-induced increase in the incidence of a disease may decrease the share
of research on the disease that is drug-related. A likely explanation is that for the diseases for
which the disease incidence is higher for the obese than it is for the normal weight research
e⁄ort is substituted from general research on the disease to obesity-speci￿c research on the
disease as the obesity rate increases.
In the analyses reported in columns 3 and 4 the logarithm of the ratio of surgery-related
research and all research is set as the dependent variable.30 The results show a negative and
statistically signi￿cant relationship between the share of surgery-related research on a disease
and the measure of technological opportunity in drug-related research on the disease. This
is both evidence against the aforementioned reverse causality explanation for the positive
relationship between drug-related research and the measure of technological opportunity
and evidence that an increase in technological opportunity in drug-related research shifts
research e⁄ort away from other types research to drug-related research. The ￿nding of no
relationship between aging-induced changes in the disease incidence and the ratio of research
that is surgery-related is as expected. The negative relationship between obesity-induced
changes in the disease incidence and the share of research on the disease that is surgery-
related again suggests the possibility that an obesity-induced increase in the incidence of a
disease shifts resources away from general research on the disease to obesity-speci￿c research
on the disease.





We present evidence on how non-pro￿t innovation and for-pro￿t innovation respond to
changes in the observable determinants of the optimal allocation of inventive activities. Our
results show that the composition of medical research across diseases responds to changes in
technological opportunity and aging-induced changes in the disease incidence. While we ￿nd
that obesity-induced changes in the disease incidence have not changed the composition of
medical research across diseases, the results suggest that an obesity-induced increase in the
incidence of a disease may have shifted research away from drug-related research and surgery-
related research on the disease and likely toward obesity-speci￿c research on the disease. Our
results also show that the composition of pharmaceutical innovation across diseases responds
to both aging- and obesity-induced changes in the relative disease incidence.
The empirical analysis was in part facilitated by our analysis of a formal model of optimal
allocation of medical research e⁄ort. The analysis enabled us to identify the structural pro-
ductivity parameters that govern technological opportunity. Our research has also demon-
strated the research potential of the massive and information rich MEDLINE biomedical
publications database for future research on the economics of innovation.
Our results on medicine and pharmaceuticals and the existing research on induced in-
novation and technological opportunity in for-pro￿t innovation suggest that there does not
exist a fundamental di⁄erence between for-pro￿t and non-pro￿t allocation mechanisms in
terms of how the allocation of inventive activity responds to changes in the characteristics
that determine the optimal allocation: academic medicine is not an ivory tower. Outcomes
under decentralized non-pro￿t allocation mechanisms are therefore not necessarily inferior
to the outcomes under for-pro￿t allocation mechanisms. We believe that this ￿nding is im-
portant for its implications to economic policy and is certainly worthy of closer attention in
future research.
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27Appendix 1: ICD-9/MESH Match
1. INFECTIOUS AND PARASITIC DISEASES
GROUP ICD-9 entry/entries MESH entry/entries
011 011 Pulmonary tuberculosis Tuberculosis, Pulmonary [C01.252.410.040.552.846.899]
034 034 Streptococcal sore throat and scarlet fever Scarlet Fever [C01.252.410.890.823]
052 052 Chickenpox Chickenpox [C02.256.466.175]
053 053 Herpes zoster Herpes Zoster [C02.256.466.423]
054 054 Herpes simplex Herpes Simplex [C02.256.466.382] *1982-
070 070 Viral hepatitis Hepatitis [C06.552.380]
075 075 Infectious mononucleosis Infectious Mononucleosis [C15.604.515.516]
110
110 Dermatophytosis
111 Dermatomycosis, other and unspeci￿ed
Tinea [C17.800.838.208.883]
Tinea Versicolor [C01.703.295.936]
112 112 Candidiasis Candidiasis [C01.703.160]
132 132 Pediculosis and phthirus infestation Lice Infestations [C03.858.211.300]
133 133 Acariasis Mite Infestations [C03.858.211.394]
NO MATCH
038 Septicemia
074 Speci￿c diseases due to Coxsackie virus
282. NEOPLASMS
GROUP ICD-9 entry/entries MESH entry/entries
150
150-159 Malignant neoplasm of digestive organs and peritoneum
211 Benign neoplasm of other parts of digestive system
Digestive System Neoplasms [C04.588.274]
Abdominal Neoplasms [C04.588.033]
Anal Gland Neoplasms [C04.588.083]
162
162 Malignant neoplasm of trachea, bronchus, and lung
163 Malignant neoplasm of pleura
Respiratory Tract Neoplasms [C04.588.894.797]
171
171 Malignant neoplasm of connective and other soft tissue
214 Lipoma
215 Other benign neoplasm of connective and other soft tissue
Soft Tissue Neoplasms [C04.588.839] *1976-
172
172 Malignant melanoma of skin
173 Other malignant neoplasm of skin
216 Benign neoplasm of skin
Skin Neoplasms [C04.588.805]
174
174 Malignant neoplasm of female breast
175 Malignant neoplasm of male breast
217 Benign neoplasm of breast
Breast Neoplasms [C04.588.180]
179
179 Malignant neoplasm of uterus, part unspeci￿ed
180 Malignant neoplasm of cervix uteri
181 Malignant neoplasm of placenta
182 Malignant neoplasm of body of uterus
183 Malignant neoplasm of ovary and other uterine adnexa
184 Malignant neoplasm of other and unspeci￿ed female genital organs
218 Uterine leiomyoma
219 Other benign neoplasm of uterus
220 Benign neoplasm of ovary
221 Benign neoplasm of other female genital organs
185 Malignant neoplasm of prostate
186 Malignant neoplasm of testis
187 Malignant neoplasm of penis and other male genital organs
222 Benign neoplasm of male genital organs
188 Malignant neoplasm of bladder
189 Malignant neoplasm of kidney and other and unspeci￿ed urinary organs
223 Benign neoplasm of kidney and other urinary organs
Genital Neoplasms, Female [C13.351.937.418]
Genital Neoplasms, Male [C04.588.945.440]
Urologic Neoplasms [C12.758.820]
200 200-208 Malignant neoplasm of lymphatic and hematopoietic tissue
Leukemia [C04.557.337]
Lymphoma [C04.557.386]
230 230-234 Carcinoma in situ Carcinoma in Situ [C04.557.470.200.240]
NO MATCH (none)
293. ENDOCRINE, NUTRITIONAL AND METABOLIC DISEASES, AND IMMUNITY DISORDERS
GROUP ICD-9 entry/entries MESH entry/entries
240
240 Simple and unspeci￿ed goiter
241 Nontoxic nodular goiter
Goiter [C19.874.283]





250 250 Diabetes mellitus Diabetes Mellitus [C18.452.394.750]
265
265 Thiamine and niacin de￿ciency states
266 De￿ciency of B-complex components
Vitamin B De￿ciency [C18.654.521.500.133.699]
272 272 Disorders of lipoid metabolism Lipid Metabolism Disorders [C18.452.584]
274 274 Gout Gout [C05.550.114.423]

















NO MATCH 256 Ovarian dysfunction
304. DISEASES OF BLOOD AND BLOOD-FORMING ORGANS
GROUP ICD-9 entry/entries MESH entry/entries
280
280 Iron de￿ciency anemias
281 Other de￿ciency anemias
282 Hereditary hemolytic anemias
283 Acquired hemolytic anemias
284 Aplastic anemia
285 Other and unspeci￿ed anemias
Anemia [C15.378.071]
288 288 Diseases of white blood cells
Agranulocytosis [C15.378.553.546.184]





GROUP ICD-9 entry/entries MESH entry/entries






299 299 Psychoses with origin speci￿c to childhood Child Development Disorders, Pervasive [F03.550.325] *1981-






301 301 Personality disorders Personality Disorders [F03.675]
302 302 Sexual deviations and disorders Sexual and Gender Disorders [F03.800]
303
303 Alcohol dependence syndrome
304 Drug dependence
305 Nondependent abuse of drugs
Substance-Related Disorders [F03.900]
314 314 Hyperkinetic syndrome of childhood Attention De￿cit Disorder with Hyperactivity [F03.550.150.150]




308 Acute reaction to stress
306 Physiological malfunction arising from mental factors
326. DISEASES OF THE NERVOUS SYSTEM AND SENSE ORGANS
GROUP ICD-9 entry/entries MESH entry/entries
320
320 Bacterial meningitis
321 Meningitis due to other organisms
322 Meningitis of unspeci￿ed cause




332 332 Parkinson￿ s disease Parkinsonian Disorders [C10.228.662.600]
340 340 Multiple sclerosis Multiple Sclerosis [C10.114.375.500]
343 343 Infantile cerebral palsy Cerebral Palsy [C10.228.140.140.254]
345 345 Epilepsy Epilepsy [C10.228.140.490]
346 346 Migraine Migraine Disorders [C10.228.140.546.399.750]
350 350-359 Disorders of the peripheral nervous system Peripheral Nervous System Diseases [C10.668.829]
361
361 Retinal detachments and defects
362 Other retinal disorders
Retinal Diseases [C11.768]
363
360 Disorders of the globe
363 Chorioretinal in￿ ammations and scars and other disorders of choroid
364 Disorders of iris and ciliary body
Uveal Diseases [C11.941]
365 365 Glaucoma Glaucoma [C11.525.381]
366 366 Cataract Cataract [C11.510.245]
367 367 Disorders of refraction and accommodation Refractive Errors [C11.744]
368
368 Visual disturbances
369 Blindness and low vision
Vision Disorders [C23.888.592.763.941]
371 371 Corneal opacity and other disorders of cornea Corneal Diseases [C11.204]
372 372 Disorders of conjunctiva Conjunctival Diseases [C11.187] *1981-
373
373 In￿ ammation of eyelids
374 Other disorders of eyelids
Eyelid Diseases [C11.338]
375 375 Disorders of lacrimal system Lacrimal Apparatus Diseases [C11.496]
380 380 Disorders of external ear Otitis Externa [C09.218.705.496]
381
381 Nonsuppurative otitis media and Eustachian tube disorders
382 Suppurative and unspeci￿ed otitis media
383 Mastoiditis and related conditions
Otitis Media [C09.218.705.663]
386 386 Vertiginous syndromes and other disorders of vestibular system Labyrinth Diseases [C09.218.568]
389 389 Hearing loss Hearing Loss [C10.597.751.418.341]
NO MATCH (none)
337. DISEASES OF THE CIRCULATORY SYSTEM
GROUP ICD-9 entry/entries MESH entry/entries
401 401-405 Hypertensive disease Hypertension [C14.907.489]
410
410 Acute myocardial infarction
412 Old myocardial infarction
Myocardial Infarction [C14.280.647.500]
413 413 Angina pectoris Angina Pectoris [C14.907.553.470.250.125]
414
414 Other forms of chronic ischemic heart disease
440 Atherosclerosis








428 428 Heart failure Heart Failure, Congestive [C14.280.434]
430 430-438 Cerebrovascular disease Cerebrovascular Disorders [C14.907.253]
444
444 Arterial embolism and thrombosis
451 Phlebitis and thrombophlebitis
452 Portal vein thrombosis
453 Other venous embolism and thrombosis
Embolism and Thrombosis [C14.907.355]
Phlebitis [C14.907.681]
454
454 Varicose veins of lower extremities
456 Varicose veins of other sites
Varicose Veins [C14.907.927]
455 455 Hemorrhoids Hemorrhoids [C14.907.449]
458 458 Hypotension Hypotension [C14.907.514]
NO MATCH (none)
348. DISEASES OF THE RESPIRATORY SYSTEM
GROUP ICD-9 entry/entries MESH entry/entries
460
460 Acute nasopharyngitis [common cold]
462 Acute pharyngitis









474 Chronic disease of tonsils and adenoids
Tonsillitis [C08.730.817]
464
464 Acute laryngitis and tracheitis






466 Acute bronchitis and bronchiolitis
490 Bronchitis, not speci￿ed as acute or chronic
491 Chronic bronchitis
Bronchitis [C08.381.495.146]
477 477 Allergic rhinitis Rhinitis [C08.460.799]
480
480 Viral pneumonia
481 Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]
482 Other bacterial pneumonia
483 Pneumonia due to other speci￿ed organism
484 Pneumonia in infectious diseases classi￿ed elsewhere
485 Bronchopneumonia, organism unspeci￿ed
486 Pneumonia, organism unspeci￿ed
514 Pulmonary congestion and hypostasis
Pneumonia [C08.381.677]
487 487 In￿ uenza In￿ uenza, Human [C08.730.310]
492 492 Emphysema Emphysema [C23.550.325]
493 493 Asthma Asthma [C08.127.108]
511 511 Pleurisy Pleurisy [C08.528.735]
NO MATCH 470 Deviated nasal septum
359. DISEASES OF THE DIGESTIVE SYSTEM
GROUP ICD-9 entry/entries MESH entry/entries
520
520 Disorders of tooth development and eruption
521 Diseases of hard tissues of teeth






522 Diseases of pulp and periapical tissues
523 Gingival and periodontal diseases
Periapical Diseases [C07.320.830]




526 526 Diseases of the jaws
Jaw Cysts [C04.182.089.530]
Granuloma, Giant Cell [C05.500.368]
*1980-
527 527 Diseases of the salivary glands Salivary Gland Diseases [C07.465.815]
528 528 Diseases of the oral soft tissues, excluding lesions speci￿c for gingiva and tongue
Stomatitis [C07.465.864]
Noma [C07.465.604]








Peptic Ulcer Hemorrhage [C06.405.227.700]
Gastrointestinal Hemorrhage [C23.550.414.788]
535
535 Gastritis and duodenitis















550 550-553 Hernia of abdominal cavity Hernia [C23.300.707]
560 560 Intestinal obstruction without mention of hernia Intestinal Obstruction [C06.405.469.531]
562 562 Diverticula of intestine
Diverticulum, Colon [C23.300.415.124]
Diverticulum, Stomach [C23.300.415.500]
574 574 Cholelithiasis Cholelithiasis [C06.130.409]
577 577 Diseases of pancreas
Pancreatitis [C06.689.750]
Pancreatic Cyst [C06.689.500]
NO MATCH 571 Chronic liver disease and cirrhosis
3610. DISEASES OF THE GENITOURINARY SYSTEM
GROUP ICD-9 entry/entries MESH entry/entries
590 590 Infections of kidney Nephritis [C12.777.419.570]
592 592 Calculus of kidney and ureter
Nephrolithiasis [C12.777.419.600]
Ureterolithiasis [C12.777.725.938]
595 595 Cystitis Cystitis [C12.777.829.495]
600
600 Hyperplasia of prostate
601 In￿ ammatory diseases of prostate
602 Other disorders of prostate
Prostatic Diseases [C12.294.565]
607 607 Disorders of penis Penile Diseases [C12.294.494]
610
610 Benign mammary dysplasias
611 Other disorders of breast
Breast Diseases [C17.800.090]
614
614 In￿ ammatory disease of ovary, fallopian tube, pelvic cellular tissue, and peritoneum
620 Nonin￿ ammatory disorders of ovary, fallopian tube, and broad ligament
Adnexal Diseases [C13.351.500.056]
615
615 In￿ ammatory diseases of uterus, except cervix
616 In￿ ammatory disease of cervix, vagina, and vulva
618 Genital prolapse
621 Disorders of uterus, not elsewhere classi￿ed
622 Nonin￿ ammatory disorders of cervix
623 Nonin￿ ammatory disorders of vagina
624 Nonin￿ ammatory disorders of vulva and perineum




617 617 Endometriosis Endometriosis [C13.351.500.163]
628 628 Infertility, female Infertility, Female [C13.351.500.365.700]
NO MATCH 627 Menopausal and postmenopausal disorders
3712. DISEASES OF THE SKIN AND SUBCUTANEOUS TISSUE
GROUP ICD-9 entry/entries MESH entry/entries
680 680 Carbuncle and furuncle Furunculosis [C01.252.410.868.820.270]
681
681 Cellulitis and abscess of ￿nger and toe
682 Other cellulitis and abscess
Cellulitis [C01.539.800.130]
684 684 Impetigo Impetigo [C01.252.410.868.820.504]
690
690 Erythematosquamous dermatosis




691 Atopic dermatitis and related conditions
692 Contact dermatitis and other eczema
Dermatitis, Atopic [C17.800.174.193]
Dermatitis, Contact [C17.800.174.255]








700 700 Corns and callosities Callosities [C17.800.428.200]
703 703 Diseases of nail Nail Diseases [C17.800.529] *1979-
704 704 Diseases of hair and hair follicles Hair Diseases [C17.800.329] *1980-
705 705 Disorders of sweat glands Sweat Gland Diseases [C17.800.946] *1976-
708 708 Urticaria Urticaria [C17.800.862.945]
NO MATCH
707 Chronic ulcer of skin
695 Erythematous conditions
693 Dermatitis due to substances taken internally
3813. DISEASES OF THE MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE
GROUP ICD-9 entry/entries MESH entry/entries
710
710 Di⁄use diseases of connective tissue
728 Disorders of muscle, ligament, and fascia






715 Osteoarthrosis and allied disorders
721 Spondylosis and allied disorders
Osteoarthritis [C05.550.114.606]
722 722 Intervertebral disc disorders Intervertebral Disk Displacement [C05.116.900.307]
726 726 Peripheral enthesopathies and allied syndromes Bursitis [C05.550.251]
734 734 Flat foot Flatfoot [C05.330.448]
735 735 Acquired deformities of toe
Hallux Valgus [C05.330.610]
Hallux Varus [C05.330.612]
737 737 Curvature of spine Spinal Curvatures [C05.116.900.800]
NO MATCH 717 Internal derangement of knee
39Appendix 2. Figures and Tables
Figure 1a.











1975 1980 1985 1990 1995 2000 2005
Year












1975 1980 1985 1990 1995 2000 2005
Year
Normal Weight Overweight Obese
Body Weight Distribution 1975-2005
40Figure 1b.


































































































































































-10 0 10 20
Percentage Effect of Aging
Effect of Change in Age Distribution and Effect of Change in Body Weight Distribution
During 1975-2005 on Potential Market Size By Disease
41Figure 2a.




















1945 1955 1965 1975 1985 1995 2005
Year
All Publications
Publications with an Abstract

































1975 1985 1995 2005
Year
(DRUG 1) Matches to an Ingredient Cohort
(DRUG 2) Matches to at Least One Ingredient
(DRUG 3) Drugs Indexed as a Major Topic
3 Measures of Drug-Related Research by Year
43Figure 2c.

































1975 1985 1995 2005
Year
(OTHER 1) No Matches to Ingredients, Drugs Not Indexed as a Major Topic
(OTHER 2) No Matches to Ingredients, Drugs Not a Major Topic, No Indexed Drugs
(OTHER 3) Surgery
3 Measures of Other Medical Research by Year
44Figure 2d.


































0 10 20 30 40
Age
Mean of Observed Probabilities Predicted values from Stage 1
Ingredient Age and Probability of Use
45Figure 2e.










































1900 1920 1940 1960 1980 2000
Assigned Year of Discovery
Ingredients Discovered by Year
46Figure 3a.




on Class￿Year and Disease ￿xed e⁄ects vs.





on Class￿Year and Disease ￿xed e⁄ects






















































52 52 52 52 52
52
52 52 52 52 52
52
52 52 52 52 52
52
52 52







53 53 53 53 53 53 53 53 53 53 53 53
53
54
54 54 54 54 54 54 54 54 54
54 54 54 54 54 54












































































































































































































172 172 172 172
172 172 172 172 172 172 172 172 172 172














174 174 174 174 174 174 179 179 179 179




















































































































































265 265 265 265
265



















































275 275 275 275 275
275
275 275 275 275 275 275 275 275 275 275
275
275 275 275
275 275 275 275 275 275 275 275 275 275 276 276 276 276 276 276 276 276
276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276 276
279
279














279 279 279 279 279 279 279
279 280 280
280




288 288 288 288 288
288 288
288 288 288 288
288
288 288 288 288
288 288 288
































































































































































































320 320 320 320 320
320 320 320 320
320 320 320
320 320 320 320 320 320



















































































































































































































366 366 366 366 366 366 366
366 366 366








366 366 366 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367 367
367 367 367 367367 367367
367
367
368 368 368 368 368 368 368368 368 368 368 368 368 368 368 368 368 368 368 368 368





























































































380 380 380 380
381





































































































413 413 413 413 413 413
413 413
413 413 413 413
413













































430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430 430
430
430 430 430 430 430 430 430 430 430 430 430

























































458 458 458 458 458








458 458 458 458
458
458 458
458 458 458 458 458 458
460 460 460 460 460 460 460 460 460 460 460460 460 460 460 460 460 460 460
460 460 460
460 460 460 460 460 460 460
460 460 461 461 461 461461 461
461
461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461 461
461
461 461 463 463
463 463 463
463 463 463 463 463 463463
463
463
463 463 463 463
463 463
463 463 463 463
463























466 466 466 466
466 466 466 466 466
466 466































480 480 480 480 480 480
480




























492 492 492 492 492
492 492 492 492 492 492 492 492
492 492 492 492 492 492492 492
492




493 493 493 493 493 493
493







































































































































535 535 535 535535 535 535 535 535 535 535 535 535 535 535 535 535 535535 535 535 535 535 535 535 535
536
536 536 536 536
536





































































































574 574 574 574
574 574
574 574 574

























590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590 590
590 590 590 590 590









































































607 607 607 607 607
607 607
607 607 607 607 607
607 607
607
607 607 607 607 607 607 607
607
607 610 610 610 610 610 610 610
610 610 610 610 610 610 610
610




































615 615 615 615 615 615 615 615 615
615 615 615 615
615 615
615 615 617 617




617 617 617 617
617
617 617 617 617 617
617 617 617 617 617





































































































































691 691 691 691
691 691 691 691 691


































698 698 698 698 698 698 698 698
698















































































































708 708 708 708
710 710 710 710 710710 710 710 710 710 710 710 710710
710
710 710 710 710 710710 710 710 710 710 710 710 710
710 710 710






715 715 715 715 715715
715














































































































737 737 737 737 737 737 737
737
737 737




















































-.15 -.1 -.05 0 .05 .1
Potential Market Size Residual
Residuals Fitted values
Residuals for All Diseases
47Figure 3b.




on Class￿Year and Disease ￿xed e⁄ects vs.





on Class￿Year and Disease ￿xed e⁄ects

































































































































































































































































































































































































275 275 275 275 275 275 275
275












276 276 276 276 276 276
276 276 276 276 276 276 276

















































































































































































































































































































































































363 363 363 363 363
363


















































371 371 401 401 401 401 401 401
401 401
401






















































414 414 414 414 414 414 414 414 414 414 414 414 414 414














































428 428 428 428 428 428














































































































































































































































































































































































































































































































































































-.1 -.05 0 .05 .1
Potential Market Size Residual
Residuals Fitted values
Residuals for 63 Diseases with Most Observations
48Figure 3c.
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50Table 1
Induced Pharmaceutical Innovation
(1) (2) (3) (4)








































Number of observations 3883 3883 3883 3883
Our statistical inference is based on pwild which is calculated using the cluster-robust standard error (clustered at the class level)
and the wild cluster bootstrapped distribution of the t-statistic (1000 iterations). Monte Carlo evidence favors this approach when the
number of clusters is small and the clusters are unbalanced (Cameron et al., 2007). The wild cluster bootstrapped standard error (1000
iterations) is presented in brackets.
51Table 2
Determinants of All Medical Research
















































































Number of observations 3884 3884 3883 3883 3796 3796
In columns 5 and 6 children￿ s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of
the standard errors and p-values.
52Table 3
Determinants of Drug-Related Medical Research
(1) (2) (3) (4) (5) (6)
Dependent variable: ln(NDRUG 1
it ) ln(NDRUG 1
it ) ln(NDRUG 2
it ) ln(NDRUG 2
it ) ln(NDRUG 3
















































































Number of observations 3730 3730 3730 3730 3697 3697
Children￿ s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.
53Table 4
Determinants of Other Medical Research
(1) (2) (3) (4) (5) (6)
Dependent variable: ln(NOTHER 1
it ) ln(NOTHER 1
it ) ln(NOTHER 2
it ) ln(NOTHER 2
it ) ln(NOTHER 3
















































































Number of observations 3796 3796 3796 3796 3723 3723
Children￿ s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.
54Table 5
Determinants of Type of Medical of Research














































































Number of observations 3697 3697 3723 3723
Children￿ s mental health diseases (299, 314, 315) are omitted. See the footnote to Table 1 for an explanation of the standard errors
and p-values.
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